Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > Thoughts on today's NR

<< Previous

Bullboard Posts

Next >>

Comment by NightHawk1987on May 25, 2020 7:25pm

93 Views

Post# 31070949

RE:RE:RE:RE:RE:RE:Thoughts on today's NR

Haha easy there Algernon. Not gonna lie, I lost a lot of respect for you. I thought we were all on the same team here. We're all after that $. Keep your eye on the prize bud. We're not asking you to be our water boy, just respectful insight is all. Like Arbour said, don't take every post to heart... good lord. Your just as bad as some others. We're all here to sift through the info, and gather info. Knowledge is power. It's up to you to believe what you want, or read what makes you upset.

<< Previous

Bullboard Posts

Next >>

Victoria Gold stock falls 82% after Yukon landslide halts production